Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sucampo Presents Cobiprostone Phase 2 Trial Results
The data were presented at the Digestive Disease Week (DDW) 2010 conference in New Orleans, Louisiana, as part of the distinguished abstract plenary session. Sucampo Pharmaceuticals said that
The data were presented at the Digestive Disease Week (DDW) 2010 conference in New Orleans, Louisiana, as part of the distinguished abstract plenary session. Sucampo Pharmaceuticals said that
Results showed Bystolic reduced sitting systolic and diastolic blood pressure (BP) when used as monotherapy and was well tolerated. Bystolic is a beta blocker approved by the FDA
Both the entities said that on April 22, 2010 at joint advisory committee meeting, FDA questioned the effectiveness of niacin included in the current Acurox formulation but cited
The licensing agreement between Spring Creek Capital and McCoy Enterprise, LLC/Vectoris Pharma, gives Spring Creek the exclusive rights to produce, market, distribute and sell products based on method
The data presented demonstrate that statistical significance versus placebo was achieved for the primary endpoint of 12-week complete spontaneous bowel movement (CSBM) overall responder for each of the
The milestone payment is part of an exclusive commercial licensing agreement for Ceplene with Meda in Europe and certain Pacific Rim countries signed by the two companies in
Premier Anna Bligh said that the grant supports the continuation of an existing collaboration with Maree Smith, an expert in Opioid research in pain at the University of
As per the agreement, TB Alliance and AstraZeneca are expected to contribute TB drug discovery projects into a joint portfolio that will be co-developed by both parties. Sharing
GlycoVaxyn said that using its proprietary technology, staphylococcal surface polysaccharides will be conjugated in-vivo to conserved protein antigens from S aureus. The efficacy of this new bioconjugate vaccine
ReGen Therapeutics said that in in-vitro studies Colostrinin has been shown to prevent the aggregation of beta-amyloid and reduce it’s toxicity to cells. Colostrinin has also been shown